<DOC>
	<DOCNO>NCT00691093</DOCNO>
	<brief_summary>This observational study patient treat fesoterodine ( Toviaz ) , fail previous treatment overactive bladder . It collect epidemiological data investigate efficacy tolerability fesoterodine .</brief_summary>
	<brief_title>Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy</brief_title>
	<detailed_description>patient older 18 year overactive bladder failure previous antimuscarinic therapy ( due lack efficacy intolerance )</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Patients older 18 year Patients OAB failure previous antimuscarinic therapy due lack efficacy : persistence storage symptom . Required symptom : micturition frequency 8 / 24 hour urgency episode ≥2 per day subjectively perceive bothersome Due intolerance : persistent and/or unacceptable adverse event Hypersensitivity active substance peanut soya excipients . History acute urinary retention ( require catheterisation ) Gastric retention Uncontrolled narrow angle glaucoma Myasthenia gravis Severe hepatic impairment ( Child Pugh C ) Concomitant use potent CYP3A4 inhibitor subject moderate severe hepatic renal impairment Severe ulcerative colitis Toxic megacolon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>observational</keyword>
</DOC>